Core Insights - On November 24, a total of 17 companies were investigated by institutions, with 10 companies being surveyed by funds, indicating a strong interest in specific stocks [1] - Among the surveyed companies, 6 attracted more than 5 funds, with Crystal Morning Technology being the most popular, receiving attention from 35 funds [1] - The total market capitalization of the surveyed A-shares includes 1 company with a market cap over 500 billion yuan, and 6 companies with market caps below 100 billion yuan [1] Company Summaries - **Crystal Morning Technology (688099)**: Received the highest interest with 35 funds participating in the survey, latest closing price at 92.72 yuan, and a 5-day price increase of 15.68% [1] - **Weili Transmission (300904)**: Attracted 19 funds, latest closing price at 69.20 yuan, with a 5-day price decrease of 2.40% [1] - **Haiyou New Materials (688680)**: Surveyed by 8 funds, latest closing price at 39.17 yuan, experiencing a significant 5-day price drop of 14.83% [1] - **Sanyuan Bio (301206)**: Engaged 7 funds, latest closing price at 27.32 yuan, with a 5-day decline of 5.07% [1] - **Dayilong (002209)**: Also received attention from 7 funds, latest closing price at 14.39 yuan, with a 5-day decrease of 5.95% [1] - **Yongdong Shares (002753)**: Participated by 5 funds, latest closing price at 8.01 yuan, with a slight increase of 3.35% over 5 days [1] - **Hengyi Petrochemical (000703)**: Surveyed by 3 funds, latest closing price at 6.96 yuan, with a 5-day decline of 7.94% [1] - **Weichai Power (000338)**: Engaged 2 funds, latest closing price at 16.60 yuan, with a 5-day decrease of 6.21% [1] - **Zhongsheng Pharmaceutical (002317)**: Attracted 1 fund, latest closing price at 24.08 yuan, with a 5-day decline of 9.20% [1] - **Meirui New Materials (300848)**: Also surveyed by 1 fund, latest closing price at 14.89 yuan, with a 5-day drop of 10.52% [1]

Summary of the Conference Call for Sanren Biological Industry and Company Overview - The conference call discusses Sanren Biological, a company involved in the production of erythritol and other sugar substitutes, particularly in the context of international trade challenges and product development strategies. Key Points and Arguments Impact of U.S. Tariffs - The U.S. imposed a preliminary anti-dumping duty of 462% on erythritol, severely hindering direct exports. Despite this, the company managed to maintain some sales through transshipment trade due to strong demand and brand recognition in the U.S. market, although sales volume decreased by 25% year-on-year from January to September [2][3][5]. Legal Actions and Market Adaptation - Some customers have filed lawsuits regarding the anti-dumping duties, which could potentially allow for legal exports if the court rules that certain blended products are exempt. The U.S. government shutdown has delayed these rulings, but a resolution is expected within the next year [2][5]. European Market Challenges - The European Union has also imposed high anti-dumping duties, leading to a halt in direct exports. The company has adjusted its product formulations to produce erythritol blends with less than 90% altritol to circumvent these tariffs, which has been gradually accepted by customers, resulting in increased demand [2][6]. Domestic Market Conditions - Domestic erythritol prices have stabilized at around $1.2 to $1.3 per kilogram, with low inventory levels across the industry. Companies are primarily producing based on sales demand, and despite price reductions for promotions, Sanren Biological has managed to maintain operational effectiveness [2][7][8]. Cost Management Strategies - The company has implemented various measures to reduce production costs, including technological improvements, energy-saving modifications, and automation. These strategies have helped mitigate the impact of anti-dumping measures from the U.S. and Europe while expanding into emerging markets in Southeast Asia, the Middle East, and South America [2][9]. New Product Development - Sanren Biological is actively developing new products such as altritol, tagatose, and cosmetic ingredients, with increasing domestic and international demand for altritol. The company has begun small-scale supply of these products and is exploring market opportunities [2][4][10][11]. Financial Considerations - The decline in bank interest rates has negatively impacted the company's financial income. However, the company plans to manage funds flexibly and explore horizontal mergers and acquisitions to enhance performance and profitability [2][14]. Future Outlook for Altritol - There is significant interest in altritol, with several companies planning large-scale production. However, the company remains cautious about large investments due to potential market oversupply and competition risks [2][15]. Resource Allocation for New Products - The company prioritizes the development of new products based on market acceptance and potential, focusing on altritol, tagatose, and various cosmetic ingredients, while ensuring efficient resource allocation [2][16]. Long-term Development Goals - Sanren Biological aims to expand its product range and contribute to the health industry through technological innovation and resource integration, striving for sustainable development and shareholder returns [2][17].

山东三元生物科技股份有限公司 投资者关系活动记录表 编号：2025-003 |  | 特定对象调研 分析师会议 | □ | | | --- | --- | --- | --- | | □ 投资者关系活动 | 媒体采访 | □ | 业绩说明会 | | □ 类别 | 新闻发布会 | □ | 路演活动 | | □ | 现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | | | | 上海万纳私募基金管理有限公司杨君弈；中信建投证券股份有限 | | | | | 公司夏克扎提·努力木、杨骥、高畅；和谐健康保险股份有限公 | | | | | 司毛一鹏；平安理财有限责任公司芶思雨；招银国际资产管理有 | | | | | 限公司张慎平；华夏理财有限责任公司何煦；广东正圆私募基金 | | | | | 管理有限公司侯昭慧；中信建投经管委财富管理部客户裘峥、赖 | | | | | 昕；北京坤溪私募基金管理有限公司李任翾；长安汇通集团有限 | | | | | 责任公司李郑浩峰；博道基金管理有限公司陈磊；上海渊泓投资 | | | | | 管理有限公司顾屹泉；淳厚基金管理有限公司顾伟；深圳安瑞置 | | | | 参 ...

证券日报网讯 11月24日晚间，三元生物发布公告称，公司于近日收到公司首次公开发行股票并在创业 板上市的保荐机构中信建投证券股份有限公司（简称"中信建投"）出具的《中信建投证券股份有限公司 关于变更山东三元生物科技股份有限公司首次公开发行股票项目持续督导保荐代表人的函》，原保荐代 表人陈磊先生因工作变动原因，不再负责公司首次公开发行股票并在创业板上市的持续督导保荐工作。 为保证公司持续督导工作的有序进行，中信建投委派邵路伟先生接替陈磊先生担任公司持续督导保荐代 表人，继续履行相关职责。 （文章来源：证券日报） ...

特此公告 关于变更保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"） 于近日收到公司首次 公开发行股票并在创业板上市的保荐机构中信建投证券股份有限公司（以下简称 "中信建投"）出具的《中信建投证券股份有限公司关于变更山东三元生物科技 股份有限公司首次公开发行股票项目持续督导保荐代表人的函》，原保荐代表人 陈磊先生因工作变动原因，不再负责公司首次公开发行股票并在创业板上市的持 续督导保荐工作。 为保证公司持续督导工作的有序进行，中信建投委派邵路伟先生（简历详见 附件）接替陈磊先生担任公司持续督导保荐代表人，继续履行相关职责。本次保 荐代表人变更后，公司持续督导期保荐代表人为邵路伟先生和张现良先生。持续 督导期至 2025 年 12 月 31 日止。 公司董事会对陈磊先生在公司首次公开发行股票项目保荐发行及持续督导 期间所做的贡献表示衷心的感谢。 证券代码：301206 证券简称：三元生物 公告编号：2025-088 山东三元生物科技股份有限公司 山东三元生物科技股份有限公司 董事会 2025 年 1 ...

Group 1: Core Insights - The financing of listed companies in the sugar substitute industry primarily aims to enhance production capacity [1] - The majority of external investments by representative companies focus on expanding upstream and downstream operations [1][6] Group 2: Financing and Investment - The main financing methods for listed companies include IPOs, private placements, and convertible bonds, with a focus on new projects and capacity enhancement [1] - Notable external investments include significant amounts such as 100 million RMB by Sanyuan Bio and 10 million RMB by Hainan Baolijian [2][3][4] Group 3: Industry Parks and Development - The number of sugar substitute industrial parks in China is limited, with major parks located in Shandong, which is recognized as a global production base [7][8] - The Dezhou High-tech Zone in Shandong has a production capacity of 1.5 million tons and a domestic market share of over 70% [8] Group 4: Mergers and Acquisitions - Recent mergers and acquisitions in the sugar substitute industry are primarily driven by midstream companies seeking to expand scale and secure upstream resources [9][12] - Key acquisitions include Huakang's purchase of Henan Yuxin Sugar Alcohol Co. for 1.098 billion RMB, aimed at increasing market share [12]

Core Insights - The trend of young consumers moving away from "sugar-free" products is evident, with a noticeable slowdown in the growth of sugar-free tea sales and a decline in the popularity of sugar substitutes [5][12][14] Industry Overview - Sugar-free tea sales growth has significantly decreased, with sales growth rates from April to September 2023 being 3.9%, 7%, 19.9%, 19.5%, 8.5%, and 6.3%, all lower than the same periods in the previous year [2] - The average price of sugar-free tea has been on the rise, increasing from 5.1 yuan per piece in 2023 to 5.6 yuan per piece by 2025, indicating that despite higher prices, total sales growth is slowing [2] - The market is dominated by established brands like Nongfu Spring and Suntory, which together hold 87.3% market share as of September 2023, up 6.4% from the previous year [7] - The second-tier brands' market share has decreased from 11.3% to 7.4%, while the third-tier brands' share has shrunk from 5.1% to 3.4%, highlighting the intensifying head effect in the industry [7][9] Consumer Behavior - The shift in consumer preferences indicates that the younger generation is moving away from extreme health consciousness towards a more indulgent lifestyle, seeking comfort in sugary beverages [5][12] - The demand for sugar substitutes, particularly erythritol, has also faced challenges, with a reported oversupply in the market as of May 2023, where domestic production capacity reached 380,000 tons per year against a global demand of only 173,000 tons [2][14] Product Innovation - There has been a lack of new hit products in the sugar-free tea market, with established products like unsweetened oolong and jasmine tea dominating nearly 70% of the market share [9] - The innovation in the sugar-free tea sector has stagnated, with brands focusing on minor innovations around existing products rather than developing new ones, leading to potential homogenization and price competition [9][11] - In contrast, the sugary tea segment has seen a surge in new product launches, with sugary tea products outnumbering sugar-free tea products significantly in recent months [10] Supplier Challenges - Suppliers of sugar substitutes are experiencing significant operational pressures, with major companies like San Yuan Bio reporting a 7.54% decline in total revenue and a 16.8% drop in net profit for the first three quarters of the year [14][19] - The industry is facing a broader trend of declining demand, leading to increased competition and financial strain on suppliers, many of whom are exploring alternative products and markets to mitigate losses [17][19]

Core Viewpoint - The company has legally obtained the production license for allulose and is currently supplying it steadily to domestic customers [2] Group 1 - The company has acquired the production license for allulose, indicating compliance with regulatory requirements [2] - The company is actively supplying allulose to domestic clients, suggesting a stable market presence [2]

Core Viewpoint - Sanwei Biological has legally obtained the production license for allulose and is currently supplying the product steadily to domestic customers [1] Company Summary - Sanwei Biological (301206.SZ) has successfully acquired the production license for allulose, indicating a significant step in its operational capabilities [1] - The company is now actively supplying allulose to domestic clients, which may enhance its market presence and revenue potential [1]

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于山东三元生物科技股份有限公司 2025 年第五次临时股东会的 法律意见书 国枫律股字[2025]A0542 号 致：山东三元生物科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第五次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《山东三元生物科技 股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程 序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜 ...